In Reply to Best Practice for Induction of Immunosuppression in Patients Treated With Daratumumab Is to Be Determined.
Publication
, Journal Article
Byrns, JS; Sanoff, SL
Published in: Am J Kidney Dis
January 2024
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Am J Kidney Dis
DOI
EISSN
1523-6838
Publication Date
January 2024
Volume
83
Issue
1
Start / End Page
116 / 117
Location
United States
Related Subject Headings
- Urology & Nephrology
- Patients
- Multiple Myeloma
- Immunosuppression Therapy
- Humans
- Antibodies, Monoclonal
- 3202 Clinical sciences
- 1117 Public Health and Health Services
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Byrns, J. S., & Sanoff, S. L. (2024). In Reply to Best Practice for Induction of Immunosuppression in Patients Treated With Daratumumab Is to Be Determined. Am J Kidney Dis, 83(1), 116–117. https://doi.org/10.1053/j.ajkd.2023.07.009
Byrns, Jennifer S., and Scott L. Sanoff. “In Reply to Best Practice for Induction of Immunosuppression in Patients Treated With Daratumumab Is to Be Determined.” Am J Kidney Dis 83, no. 1 (January 2024): 116–17. https://doi.org/10.1053/j.ajkd.2023.07.009.
Byrns JS, Sanoff SL. In Reply to Best Practice for Induction of Immunosuppression in Patients Treated With Daratumumab Is to Be Determined. Am J Kidney Dis. 2024 Jan;83(1):116–7.
Byrns, Jennifer S., and Scott L. Sanoff. “In Reply to Best Practice for Induction of Immunosuppression in Patients Treated With Daratumumab Is to Be Determined.” Am J Kidney Dis, vol. 83, no. 1, Jan. 2024, pp. 116–17. Pubmed, doi:10.1053/j.ajkd.2023.07.009.
Byrns JS, Sanoff SL. In Reply to Best Practice for Induction of Immunosuppression in Patients Treated With Daratumumab Is to Be Determined. Am J Kidney Dis. 2024 Jan;83(1):116–117.
Published In
Am J Kidney Dis
DOI
EISSN
1523-6838
Publication Date
January 2024
Volume
83
Issue
1
Start / End Page
116 / 117
Location
United States
Related Subject Headings
- Urology & Nephrology
- Patients
- Multiple Myeloma
- Immunosuppression Therapy
- Humans
- Antibodies, Monoclonal
- 3202 Clinical sciences
- 1117 Public Health and Health Services
- 1103 Clinical Sciences